https://www.selleckchem.com/pr....oducts/proteinase-k.
The strong CYP3A4 inhibitor ritonavir, increased exposure to ivacaftor 7 times. Our data support current recommendations for dose adjustment of ivacaftor in case of co-treatment with CYP3A4 inhibitors in people with CF. However, exposure to ivacaftor was higher in healthy subjects than in CF patients. Further study is needed to investigate the cause and implication of this difference. Our data support current recommendations for dose adjustment of ivacaftor in case of co-treatment with CYP3A4 inhibitors in people with CF. However,
Curtir
Comentario
Compartilhar
